Meet DelveInsight in BioEurope '16

  • Home Blog Meet delveinsight in bioeurope 16

Meet DelveInsight in BioEurope '16

Nov 02, 2016

p2-n

Downloads

Article in PDF

Recent Articles
  1. DelveInsight’s Oncology based Reports, 2015
  2. PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016
  3. Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track fo...
  4. Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork o...
  5. Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVY...
us-tariffs-2025-impact-healthcare-pharma-strategies
Articles

Navigating U.S. Tariffs in 2025: Impacts and Strategies for Pharma and Healthcare

pharma-news-for-boston-scientific-roche-northstrive
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Boston Scientific Pushes Forward Despite $200M Tariff Challenge; Northstrive Biosciences Gets FDA Green Light to Advance EL-22 Obesity Trial; Roche Acts Swiftly to Offset U.S. Tariff Impact with Global Engagements; Verastem Oncology Secures IND Clearance for KRAS G12D Inhibitor Trial; BlackfinBio Gets FDA OK for Phase I/II Trial of BFB-101 in SPG47

ai-in-mental-health-diagnosis-and-treatment
Articles

Exploring the Impact of AI in Mental Health: How it is Going to Revolutionize Diagnosis and Treatment for a Better Tomorrow?

BioEurope
Conference
DelveInsight
loader